June 22 — Vice Minister of Commerce and deputy chief trade negotiator Ling Ji met with a delegation from the Asia‑Pacific Medical Technology Association and member firms to discuss the operating environment and concerns of foreign medtech companies in China. Ling said that during the 15th Five‑Year Plan period China will accelerate development of biopharma and other emerging pillar industries, advance the Healthy China agenda, and welcomes multinational pharmaceutical and medtech companies to de

June 22 — Vice Minister of Commerce and deputy chief trade negotiator Ling Ji met with a delegation from the Asia‑Pacific Medical Technology Association and member firms to discuss the operating environment and concerns of foreign medtech companies in China. Ling said that during the 15th Five‑Year Plan period China will accelerate development of biopharma and other emerging pillar industries, advance the Healthy China agenda, and welcomes multinational pharmaceutical and medtech companies to deepen cooperation, expand in‑China R&D, and increase localization of production and supply chains to help safeguard global pharmaceutical supply‑chain stability. The association and member firms said they see significant market potential in China and plan to increase investment, deepen local partnerships and intensify regional technology exchanges.